LONG BEACH, Calif.--(BUSINESS WIRE)--Rocket Lab USA, Inc. (Nasdaq: RKLB) (“Rocket Lab”, “the Company”, “we,” “us,” or “our”), a global leader in launch services and space systems, today shared the financial results for fiscal third quarter, ended September 30, 2024.
Rocket Lab founder and CEO, Sir Peter Beck, said: “In the third quarter 2024 we once again executed against our end-to-end space strategy with successes and key achievements reached across small and medium launch, as well as space systems. Revenue grew 55% year-on-year to $105 million and we continue to see strong demand growth with our backlog at $1.05 billion. Significant achievements for the quarter included signing a launch service agreement for multiple launches on Neutron with a confidential commercial satellite constellation customer; successfully launching twelve Electron launches year-to-date, making 2024 a record year for launches with more still to come; signing $55 million in new Electron launches, further cementing Electron’s position as a global launch leader; and being selected by NASA to complete a study contract for a proposal to retrieve samples from Mars and return them to Earth as part of a world-first mission. We expect to close out the year strongly with more Electron launches scheduled in November and December, alongside continued progress across Neutron and space systems, that is behind our guidance for a record $125-$135 million revenue quarter in Q4.”
Business Highlights for the Third Quarter 2024, plus updates since September 30, 2024.
Electron:
- Achieved a new annual launch record of 12 Electron launches to date, with more scheduled across November and December 2024. Electron is the world’s third most-frequently launched rocket annually by vehicle type and remains the United States’ second most-frequently launched rocket annually.
- Signed several new Electron launch contracts in Q3 2024 with a total value of $55m, demonstrating an increased average selling price of $8.4m and showcasing a 67% pricing increase since the rocket’s debut launch.
- Successful Electron launches for three separate commercial satellite constellation operators in Q3, including two missions launched within just eight days. In addition to these, Electron’s most recent mission, launched in the fourth quarter on November 5th, 2024, included an expedited turnaround of just 10 weeks between contract signing and launch.
Neutron:
- Signed a launch service agreement for multiple launches on Neutron with a confidential commercial satellite constellation operator that signifies the beginning of a productive collaboration that could see Neutron deploy the entire constellation.
- Announced a federal defense contract that supports Neutron and the development of its Archimedes engine with the U.S. Air Force’s Research Laboratory.
- Doubled engine testing cadence for Archimedes over the quarter at Rocket Lab’s engine test site in Mississippi, alongside strong production execution at the Company’s Engine Development Complex in California which included multiple engines manufactured, assembled, and shipped for engine testing.
- Significant progress made across Neutron’s structures and infrastructure, including the completion of construction on the rocket’s Assembly, Integration, and Test (A.I.T.) facility in Virginia.
- Well-positioned to on-ramp to the U.S. Space Force’s National Security Space Launch (NSSL) Lane 1 program, which began accepting proposals in November 2024 to on-ramp new launch providers to an indefinite delivery indefinite quantity (IDIQ) contract valued at $5.6 billion over a five-year period.
Space Systems:
- Completed production and delivery of two spacecraft on time and on budget for NASA’s ESCAPADE mission to Mars.
- Selected by NASA to complete a study contract for a proposal to retrieve samples from Mars and return them to Earth, a first-of-its-kind mission.
- Completed two new spacecraft for Varda Space Industries to conduct the 2nd and 3rd missions to return in-space manufacturing capsules to Earth.
- Executed on schedule against the Company’s $515 million prime contract with the Space Development Agency to build 18 spacecraft for its Tranche 2 Transport Layer program.
Fourth Quarter 2024 Guidance
For the fourth quarter of 2024, Rocket Lab expects:
- Revenue between $125 million and $135 million.
- GAAP Gross Margins between 26% and 28%.
- Non-GAAP Gross Margins between 32% and 34%.
- GAAP Operating Expenses between $84 million and $86 million.
- Non-GAAP Operating Expenses between $75 million and $77 million.
- Expected Interest Expense (Income), net $1.5 million.
- Adjusted EBITDA loss of $27 million and $29 million.
- Basic Shares Outstanding of 501 million.
See “Use of Non-GAAP Financial Measures” below for an explanation of our use of Non-GAAP financial measures, and the reconciliation of historical Non-GAAP measures to the comparable GAAP measures in the tables attached to this press release. We have not provided a reconciliation for the forward-looking Non-GAAP Gross Margin, Non-GAAP Operating Expenses or Adjusted EBITDA expectations for Q4 2024 described above because, without unreasonable efforts, we are unable to predict with reasonable certainty the amount and timing of adjustments that are used to calculate these non-GAAP financial measures, particularly related to stock-based compensation and its related tax effects. Stock-based compensation is currently expected to range from $12 million to $14 million in Q4 2024.
Conference Call Information
Rocket Lab will host a conference call for investors at 2 p.m. PT (5 p.m. ET) today to discuss these business highlights and financial results for our third quarter, to provide our outlook for the fourth quarter, and other updates.
The live webcast and a replay of the webcast will be available on Rocket Lab’s Investor Relations website: https://investors.rocketlabusa.com/events-and-presentations/events
+ About Rocket Lab
Founded in 2006, Rocket Lab is an end-to-end space company with an established track record of mission success. We deliver reliable launch services, satellite manufacture, spacecraft components, and on-orbit management solutions that make it faster, easier, and more affordable to access space. Headquartered in Long Beach, California, Rocket Lab designs and manufactures the Electron small orbital launch vehicle, a family of spacecraft platforms, and the Company is developing the large Neutron launch vehicle for constellation deployment. Since its first orbital launch in January 2018, Rocket Lab’s Electron launch vehicle has become the second most frequently launched U.S. rocket annually and has delivered 198 satellites to orbit for private and public sector organizations, enabling operations in national security, scientific research, space debris mitigation, Earth observation, climate monitoring, and communications. Rocket Lab’s spacecraft platforms have been selected to support NASA missions to the Moon and Mars, as well as the first private commercial mission to Venus. Rocket Lab has three launch pads at two launch sites, including two launch pads at a private orbital launch site located in New Zealand and a third launch pad in Virginia. To learn more, visit www.rocketlabusa.com.
+ Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. We intend such forward-looking statements to be covered by the safe harbor provisions for forward looking statements contained in Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). All statements contained in this press release other than statements of historical fact, including, without limitation, statements regarding our expectations of financial results for the fourth quarter of 2024, launch and space systems operations, launch schedule and window, safe and repeatable access to space, Neutron development, operational expansion and business strategy are forward-looking statements. The words “believe,” “may,” “will,” “estimate,” “potential,” “continue,” “anticipate,” “intend,” “expect,” “strategy,” “future,” “could,” “would,” “project,” “plan,” “target,” and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements use these words or expressions. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including but not limited to the factors, risks and uncertainties included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, as such factors may be updated from time to time in our other filings with the Securities and Exchange Commission (the “SEC”), accessible on the SEC’s website at www.sec.gov and the Investor Relations section of our website at www.rocketlabusa.com, which could cause our actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.
+ Use of Non-GAAP Financial Measures
We supplement the reporting of our financial information determined under Generally Accepted Accounting Principles in the United States of America (“GAAP”) with certain non-GAAP financial information. The non-GAAP financial information presented excludes certain significant items that may not be indicative of, or are unrelated to, results from our ongoing business operations. We believe that these non-GAAP measures provide investors with additional insight into the company's ongoing business performance. These non-GAAP measures should not be considered in isolation or as a substitute for the related GAAP measures, and other companies may define such measures differently. We encourage investors to review our financial statements and publicly filed reports in their entirety and not to rely on any single financial measure. Reconciliation of the non-GAAP financial information to the corresponding GAAP measures for the historical periods disclosed are included at the end of the tables in this press release. We have not provided a reconciliation for forward-looking non-GAAP financial measures because, without unreasonable efforts, we are unable to predict with reasonable certainty the amount and timing of adjustments that are used to calculate these non-GAAP financial measures, particularly related to stock-based compensation and its related tax effects. The following definitions are provided:
+ Adjusted EBITDA
EBITDA is defined as earnings before interest, taxes, depreciation and amortization. Adjusted EBITDA further excludes items of income or loss that we characterize as unrepresentative of our ongoing operations. Such items are excluded from net income or loss to determine Adjusted EBITDA. Management believes this measure provides investors meaningful insight into results from ongoing operations.
+ Other Non-GAAP Financial Measures
Non-GAAP gross profit, research and development, net, selling, general and administrative, operating expenses, operating loss and total other income (expense), net, further excludes items of income or loss that we characterize as unrepresentative of our ongoing operations. Such items are excluded from the applicable GAAP financial measure. Management believes these non-GAAP measures provide investors meaningful insight into results from ongoing operations.
ROCKET LAB U.S.A., INC. AND SUBSIDIARIES |
||||||||||||||||
CONSOLIDATED STATEMENTS OF OPERATIONS |
||||||||||||||||
FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2024 AND 2023 |
||||||||||||||||
(unaudited; in thousands, except share and per share data) |
||||||||||||||||
|
|
Three Months Ended September 30, |
|
Nine Months Ended September 30, |
||||||||||||
|
|
2024 |
|
2023 |
|
2024 |
|
2023 |
||||||||
Revenues |
|
$ |
104,808 |
|
|
$ |
67,661 |
|
|
$ |
303,826 |
|
|
$ |
184,601 |
|
Cost of revenues |
|
|
76,812 |
|
|
|
52,694 |
|
|
|
224,494 |
|
|
|
148,684 |
|
Gross profit |
|
|
27,996 |
|
|
|
14,967 |
|
|
|
79,332 |
|
|
|
35,917 |
|
Operating expenses: |
|
|
|
|
|
|
|
|
||||||||
Research and development, net |
|
|
47,723 |
|
|
|
26,626 |
|
|
|
126,139 |
|
|
|
81,566 |
|
Selling, general and administrative |
|
|
32,172 |
|
|
|
27,200 |
|
|
|
91,445 |
|
|
|
84,386 |
|
Total operating expenses |
|
|
79,895 |
|
|
|
53,826 |
|
|
|
217,584 |
|
|
|
165,952 |
|
Operating loss |
|
|
(51,899 |
) |
|
|
(38,859 |
) |
|
|
(138,252 |
) |
|
|
(130,035 |
) |
Other income (expense): |
|
|
|
|
|
|
|
|
||||||||
Interest expense, net |
|
|
(454 |
) |
|
|
(1,413 |
) |
|
|
(2,176 |
) |
|
|
(2,843 |
) |
Loss on foreign exchange |
|
|
(490 |
) |
|
|
(120 |
) |
|
|
(465 |
) |
|
|
(76 |
) |
Other income, net |
|
|
1,848 |
|
|
|
1,176 |
|
|
|
3,152 |
|
|
|
3,519 |
|
Total other income (expense), net |
|
|
904 |
|
|
|
(357 |
) |
|
|
511 |
|
|
|
600 |
|
Loss before income taxes |
|
|
(50,995 |
) |
|
|
(39,216 |
) |
|
|
(137,741 |
) |
|
|
(129,435 |
) |
Provision for income taxes |
|
|
(944 |
) |
|
|
(1,352 |
) |
|
|
(89 |
) |
|
|
(2,639 |
) |
Net loss |
|
$ |
(51,939 |
) |
|
$ |
(40,568 |
) |
|
$ |
(137,830 |
) |
|
$ |
(132,074 |
) |
Net loss per share attributable to Rocket Lab USA, Inc.: |
|
|
|
|
|
|
|
|
||||||||
Basic and diluted |
|
$ |
(0.10 |
) |
|
$ |
(0.08 |
) |
|
$ |
(0.28 |
) |
|
$ |
(0.28 |
) |
Weighted-average common shares outstanding: |
|
|
|
|
|
|
|
|
||||||||
Basic and diluted |
|
|
497,701,715 |
|
|
|
484,034,071 |
|
|
|
493,976,025 |
|
|
|
480,018,578 |
|
ROCKET LAB U.S.A., INC. AND SUBSIDIARIES |
||||||||
CONSOLIDATED BALANCE SHEETS |
||||||||
AS OF SEPTEMBER 30, 2024 AND DECEMBER 31, 2023 |
||||||||
(unaudited; in thousands, except share and per share data) |
||||||||
|
|
September 30,
|
|
December 31, |
||||
|
|
(unaudited) |
|
2023 |
||||
Assets |
|
|
|
|
||||
Current assets: |
|
|
|
|
||||
Cash and cash equivalents |
|
$ |
292,470 |
|
|
$ |
162,518 |
|
Marketable securities, current |
|
|
149,919 |
|
|
|
82,255 |
|
Accounts receivable, net |
|
|
22,148 |
|
|
|
35,176 |
|
Contract assets |
|
|
49,461 |
|
|
|
12,951 |
|
Inventories |
|
|
114,435 |
|
|
|
107,857 |
|
Prepaids and other current assets |
|
|
67,066 |
|
|
|
66,949 |
|
Assets held for sale |
|
|
— |
|
|
|
9,016 |
|
Total current assets |
|
|
695,499 |
|
|
|
476,722 |
|
Non-current assets: |
|
|
|
|
||||
Property, plant and equipment, net |
|
|
170,983 |
|
|
|
145,409 |
|
Intangible assets, net |
|
|
61,582 |
|
|
|
68,094 |
|
Goodwill |
|
|
71,020 |
|
|
|
71,020 |
|
Right-of-use assets - operating leases |
|
|
53,985 |
|
|
|
59,401 |
|
Right-of-use assets - finance leases |
|
|
14,518 |
|
|
|
14,987 |
|
Marketable securities, non-current |
|
|
61,292 |
|
|
|
79,247 |
|
Restricted cash |
|
|
4,322 |
|
|
|
3,916 |
|
Deferred income tax assets, net |
|
|
1,419 |
|
|
|
3,501 |
|
Other non-current assets |
|
|
18,409 |
|
|
|
18,914 |
|
Total assets |
|
$ |
1,153,029 |
|
|
$ |
941,211 |
|
Liabilities and Stockholders’ Equity |
|
|
|
|
||||
Current liabilities: |
|
|
|
|
||||
Trade payables |
|
$ |
42,434 |
|
|
$ |
29,303 |
|
Accrued expenses |
|
|
8,063 |
|
|
|
5,590 |
|
Employee benefits payable |
|
|
19,335 |
|
|
|
16,342 |
|
Contract liabilities |
|
|
167,129 |
|
|
|
139,338 |
|
Current installments of long-term borrowings |
|
|
11,758 |
|
|
|
17,764 |
|
Other current liabilities |
|
|
20,480 |
|
|
|
15,036 |
|
Total current liabilities |
|
|
269,199 |
|
|
|
223,373 |
|
Non-current liabilities: |
|
|
|
|
||||
Convertible senior notes, net |
|
|
344,865 |
|
|
|
— |
|
Long-term borrowings, net, excluding current installments |
|
|
46,915 |
|
|
|
87,587 |
|
Non-current operating lease liabilities |
|
|
51,906 |
|
|
|
56,099 |
|
Non-current finance lease liabilities |
|
|
15,042 |
|
|
|
15,238 |
|
Deferred tax liabilities |
|
|
726 |
|
|
|
426 |
|
Other non-current liabilities |
|
|
4,541 |
|
|
|
3,944 |
|
Total liabilities |
|
|
733,194 |
|
|
|
386,667 |
|
COMMITMENTS AND CONTINGENCIES |
|
|
|
|
||||
Stockholders’ equity: |
|
|
|
|
||||
Common stock, $0.0001 par value; authorized shares: 2,500,000,000; issued and outstanding shares: 499,700,976 and 488,923,055 at September 30, 2024 and December 31, 2023, respectively |
|
|
50 |
|
|
|
49 |
|
Additional paid-in capital |
|
|
1,178,828 |
|
|
|
1,176,484 |
|
Accumulated deficit |
|
|
(761,356 |
) |
|
|
(623,526 |
) |
Accumulated other comprehensive income |
|
|
2,313 |
|
|
|
1,537 |
|
Total stockholders’ equity |
|
|
419,835 |
|
|
|
554,544 |
|
Total liabilities and stockholders’ equity |
|
$ |
1,153,029 |
|
|
$ |
941,211 |
|
ROCKET LAB U.S.A., INC. AND SUBSIDIARIES |
||||||||
CONSOLIDATED STATEMENTS OF CASH FLOWS |
||||||||
FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2024 AND 2023 |
||||||||
(unaudited; in thousands) |
||||||||
|
|
For the Nine Months Ended
|
||||||
|
|
2024 |
|
2023 |
||||
CASH FLOWS FROM OPERATING ACTIVITIES: |
|
|
|
|
||||
Net loss |
|
$ |
(137,830 |
) |
|
$ |
(132,074 |
) |
Adjustments to reconcile net loss to net cash used in operating activities: |
|
|
|
|
||||
Depreciation and amortization |
|
|
24,516 |
|
|
|
21,577 |
|
Stock-based compensation expense |
|
|
39,944 |
|
|
|
43,398 |
|
(Gain) loss on disposal of assets |
|
|
(2,356 |
) |
|
|
240 |
|
Loss on extinguishment of long-term debt |
|
|
1,330 |
|
|
|
— |
|
Amortization of debt issuance costs and discount |
|
|
2,272 |
|
|
|
2,166 |
|
Noncash lease expense |
|
|
4,437 |
|
|
|
4,062 |
|
Change in the fair value of contingent consideration |
|
|
(218 |
) |
|
|
1,138 |
|
Accretion of marketable securities purchased at a discount |
|
|
(2,272 |
) |
|
|
(3,399 |
) |
Deferred income taxes |
|
|
2,310 |
|
|
|
644 |
|
Changes in operating assets and liabilities: |
|
|
|
|
||||
Accounts receivable, net |
|
|
12,928 |
|
|
|
13,798 |
|
Contract assets |
|
|
(36,510 |
) |
|
|
(3,592 |
) |
Inventories |
|
|
(7,118 |
) |
|
|
(10,933 |
) |
Prepaids and other current assets |
|
|
1,951 |
|
|
|
(15,819 |
) |
Other non-current assets |
|
|
544 |
|
|
|
(10,712 |
) |
Trade payables |
|
|
13,853 |
|
|
|
12,026 |
|
Accrued expenses |
|
|
2,980 |
|
|
|
(2,187 |
) |
Employee benefits payables |
|
|
3,525 |
|
|
|
5,285 |
|
Contract liabilities |
|
|
27,791 |
|
|
|
25,450 |
|
Other current liabilities |
|
|
4,088 |
|
|
|
(4,632 |
) |
Non-current lease liabilities |
|
|
(4,321 |
) |
|
|
(3,316 |
) |
Other non-current liabilities |
|
|
1,653 |
|
|
|
230 |
|
Net cash used in operating activities |
|
|
(46,503 |
) |
|
|
(56,650 |
) |
CASH FLOWS FROM INVESTING ACTIVITIES: |
|
|
|
|
||||
Purchases of property, equipment and software |
|
|
(45,539 |
) |
|
|
(44,293 |
) |
Proceeds on disposal of assets, net |
|
|
11,756 |
|
|
|
— |
|
Cash paid for asset acquisition |
|
|
— |
|
|
|
(16,934 |
) |
Purchases of marketable securities |
|
|
(149,548 |
) |
|
|
(207,266 |
) |
Maturities of marketable securities |
|
|
102,930 |
|
|
|
219,340 |
|
Net cash used in investing activities |
|
|
(80,401 |
) |
|
|
(49,153 |
) |
CASH FLOWS FROM FINANCING ACTIVITIES: |
|
|
|
|
||||
Proceeds from the exercise of stock options |
|
|
2,074 |
|
|
|
2,293 |
|
Proceeds from Employee Stock Purchase Plan |
|
|
4,098 |
|
|
|
3,780 |
|
Proceeds from sale of employees restricted stock units to cover taxes |
|
|
14,991 |
|
|
|
12,390 |
|
Minimum tax withholding paid on behalf of employees for restricted stock units |
|
|
(15,169 |
) |
|
|
(12,352 |
) |
Payment of contingent consideration |
|
|
— |
|
|
|
(1,000 |
) |
Purchase of capped calls related to issuance of convertible senior notes |
|
|
(43,168 |
) |
|
|
— |
|
Proceeds from issuance of convertible senior notes |
|
|
355,000 |
|
|
|
— |
|
Repayments on Trinity Loan Agreement |
|
|
(48,853 |
) |
|
|
— |
|
Payment of debt issuance costs |
|
|
(12,205 |
) |
|
|
— |
|
Finance lease principal payments |
|
|
(269 |
) |
|
|
(248 |
) |
Net cash provided by financing activities |
|
|
256,499 |
|
|
|
4,863 |
|
Effect of exchange rate changes on cash and cash equivalents |
|
|
763 |
|
|
|
(439 |
) |
Net increase (decrease) in cash and cash equivalents and restricted cash |
|
|
130,358 |
|
|
|
(101,379 |
) |
Cash and cash equivalents, and restricted cash, beginning of period |
|
|
166,434 |
|
|
|
245,871 |
|
Cash and cash equivalents, and restricted cash, end of period |
|
$ |
296,792 |
|
|
$ |
144,492 |
|
ROCKET LAB U.S.A., INC. AND SUBSIDIARIES |
||||||||||||||||
RECONCILIATION OF NON-GAAP FINANCIAL MEASURES |
||||||||||||||||
FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2024 AND 2023 |
||||||||||||||||
(unaudited; in thousands) |
||||||||||||||||
The tables provided below reconcile the non-GAAP financial measures Adjusted EBITDA, Non-GAAP gross profit, Non-GAAP research and development, net, Non-GAAP selling, general and administrative, Non-GAAP operating expenses, Non-GAAP operating loss and Non-GAAP total other income (expense), net with the most directly comparable GAAP financial measures. See above for additional information on the use of these non-GAAP financial measures. |
||||||||||||||||
|
|
Three Months Ended
|
|
Nine Months Ended
|
||||||||||||
|
|
2024 |
|
2023 |
|
2024 |
|
2023 |
||||||||
NET LOSS |
|
$ |
(51,939 |
) |
|
$ |
(40,568 |
) |
|
$ |
(137,830 |
) |
|
$ |
(132,074 |
) |
Depreciation |
|
|
4,793 |
|
|
|
4,237 |
|
|
|
14,513 |
|
|
|
11,463 |
|
Amortization |
|
|
3,302 |
|
|
|
3,555 |
|
|
|
10,003 |
|
|
|
10,114 |
|
Stock-based compensation expense |
|
|
12,896 |
|
|
|
14,098 |
|
|
|
39,944 |
|
|
|
43,398 |
|
Transaction costs |
|
|
23 |
|
|
|
142 |
|
|
|
407 |
|
|
|
311 |
|
Interest expense, net |
|
|
454 |
|
|
|
1,413 |
|
|
|
2,176 |
|
|
|
2,843 |
|
Change in fair value of contingent consideration |
|
|
— |
|
|
|
(462 |
) |
|
|
(218 |
) |
|
|
1,138 |
|
Performance reserve escrow |
|
|
— |
|
|
|
1,800 |
|
|
|
— |
|
|
|
5,426 |
|
Provision for income taxes |
|
|
944 |
|
|
|
1,352 |
|
|
|
89 |
|
|
|
2,639 |
|
Loss on foreign exchange |
|
|
490 |
|
|
|
120 |
|
|
|
465 |
|
|
|
76 |
|
Accretion of marketable securities purchased at a discount |
|
|
(666 |
) |
|
|
(1,447 |
) |
|
|
(2,272 |
) |
|
|
(3,601 |
) |
(Gain) loss on disposal of assets |
|
|
(1,164 |
) |
|
|
213 |
|
|
|
(2,356 |
) |
|
|
240 |
|
Employee retention credit |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(3,841 |
) |
Loss on extinguishment of debt |
|
|
— |
|
|
|
— |
|
|
|
1,330 |
|
|
|
— |
|
ADJUSTED EBITDA |
|
$ |
(30,867 |
) |
|
$ |
(15,547 |
) |
|
$ |
(73,749 |
) |
|
$ |
(61,868 |
) |
|
|
Three Months Ended
|
|
Nine Months Ended
|
||||||||||||
|
|
2024 |
|
2023 |
|
2024 |
|
2023 |
||||||||
GAAP Gross profit |
|
$ |
27,996 |
|
|
$ |
14,967 |
|
|
$ |
79,332 |
|
|
$ |
35,917 |
|
Stock-based compensation |
|
|
3,029 |
|
|
|
3,182 |
|
|
|
10,205 |
|
|
|
10,325 |
|
Amortization of purchased intangibles and favorable lease |
|
|
1,763 |
|
|
|
1,710 |
|
|
|
5,247 |
|
|
|
5,129 |
|
Performance reserve escrow |
|
|
— |
|
|
|
76 |
|
|
|
— |
|
|
|
209 |
|
Employee retention credit |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(2,130 |
) |
Non-GAAP Gross profit |
|
$ |
32,788 |
|
|
$ |
19,935 |
|
|
$ |
94,784 |
|
|
$ |
49,450 |
|
Non-GAAP Gross margin |
|
|
31.3 |
% |
|
|
29.5 |
% |
|
|
31.2 |
% |
|
|
26.8 |
% |
|
|
|
|
|
|
|
|
|
||||||||
GAAP Research and development, net |
|
$ |
47,723 |
|
|
$ |
26,626 |
|
|
$ |
126,139 |
|
|
$ |
81,566 |
|
Stock-based compensation |
|
|
(4,626 |
) |
|
|
(6,219 |
) |
|
|
(13,660 |
) |
|
|
(17,893 |
) |
Amortization of purchased intangibles and favorable lease |
|
|
(302 |
) |
|
|
(315 |
) |
|
|
(686 |
) |
|
|
(333 |
) |
Employee retention credit |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
631 |
|
Non-GAAP Research and development, net |
|
$ |
42,795 |
|
|
$ |
20,092 |
|
|
$ |
111,793 |
|
|
$ |
63,971 |
|
|
|
|
|
|
|
|
|
|
||||||||
GAAP Selling, general and administrative |
|
$ |
32,172 |
|
|
$ |
27,200 |
|
|
$ |
91,445 |
|
|
$ |
84,386 |
|
Stock-based compensation |
|
|
(5,241 |
) |
|
|
(4,697 |
) |
|
|
(16,079 |
) |
|
|
(15,180 |
) |
Amortization of purchased intangibles and favorable lease |
|
|
(960 |
) |
|
|
(1,378 |
) |
|
|
(3,274 |
) |
|
|
(4,207 |
) |
Transaction costs |
|
|
(23 |
) |
|
|
(142 |
) |
|
|
(407 |
) |
|
|
(311 |
) |
Performance reserve escrow |
|
|
— |
|
|
|
(1,724 |
) |
|
|
— |
|
|
|
(5,217 |
) |
Change in fair value of contingent consideration |
|
|
— |
|
|
|
462 |
|
|
|
218 |
|
|
|
(1,138 |
) |
Employee retention credit |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
1,080 |
|
Non-GAAP Selling, general and administrative |
|
$ |
25,948 |
|
|
$ |
19,721 |
|
|
$ |
71,903 |
|
|
$ |
59,413 |
|
|
|
|
|
|
|
|
|
|
||||||||
GAAP Operating expenses |
|
$ |
79,895 |
|
|
$ |
53,826 |
|
|
$ |
217,584 |
|
|
$ |
165,952 |
|
Stock-based compensation |
|
|
(9,867 |
) |
|
|
(10,916 |
) |
|
|
(29,739 |
) |
|
|
(33,073 |
) |
Amortization of purchased intangibles and favorable lease |
|
|
(1,262 |
) |
|
|
(1,693 |
) |
|
|
(3,960 |
) |
|
|
(4,540 |
) |
Transaction costs |
|
|
(23 |
) |
|
|
(142 |
) |
|
|
(407 |
) |
|
|
(311 |
) |
Performance reserve escrow |
|
|
— |
|
|
|
(1,724 |
) |
|
|
— |
|
|
|
(5,217 |
) |
Change in fair value of contingent consideration |
|
|
— |
|
|
|
462 |
|
|
|
218 |
|
|
|
(1,138 |
) |
Employee retention credit |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
1,711 |
|
Non-GAAP Operating expenses |
|
$ |
68,743 |
|
|
$ |
39,813 |
|
|
$ |
183,696 |
|
|
$ |
123,384 |
|
|
|
|
|
|
|
|
|
|
||||||||
GAAP Operating loss |
|
$ |
(51,899 |
) |
|
$ |
(38,859 |
) |
|
$ |
(138,252 |
) |
|
$ |
(130,035 |
) |
Total non-GAAP adjustments |
|
|
15,944 |
|
|
|
18,981 |
|
|
|
49,340 |
|
|
|
56,101 |
|
Non-GAAP Operating loss |
|
$ |
(35,955 |
) |
|
$ |
(19,878 |
) |
|
$ |
(88,912 |
) |
|
$ |
(73,934 |
) |
|
|
|
|
|
|
|
|
|
||||||||
GAAP Total other income (expense), net |
|
$ |
904 |
|
|
$ |
(357 |
) |
|
$ |
511 |
|
|
$ |
600 |
|
Loss on foreign exchange |
|
|
490 |
|
|
|
120 |
|
|
|
465 |
|
|
|
76 |
|
(Gain) loss on disposal of assets |
|
|
(1,164 |
) |
|
|
213 |
|
|
|
(2,356 |
) |
|
|
240 |
|
Loss on extinguishment of debt |
|
|
— |
|
|
|
— |
|
|
|
1,330 |
|
|
|
— |
|
Non-GAAP Total other income (expense), net |
|
$ |
230 |
|
|
$ |
(24 |
) |
|
$ |
(50 |
) |
|
$ |
916 |
|
